The World Health Organization (WHO) operates a prequalification programme to assess the quality, safety and efficacy of products that address global public health priorities. Pre-qualified products are listed on the WHO website as eligible for procurement, giving purchasing agencies such as UNICEF a range of quality-assured diagnostics, medicines and vaccines from which to choose. Charles River Associates was asked to support the development of a new financing arrangement that addressed the needs of all stakeholders, including industry groups, key partners and the WHO.
To read more, click the link below.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...